Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin

Table 1

Baseline patient and disease characteristics.

Characteristics	𝑁=21
Median age; years (range)	59 (26–72)
Male gender (%)	14 (66.7)
Diagnosis (%)
Acute myeloid leukemia	4
Chronic lymphocytic leukemia	3
Chronic myeloid leukemia (blast crisis)	2
B-cell NHL	9
T-cell NHL	2
Hemophagocytic syndrome	1
Disease relapse risk* (%)
Standard risk	15 (71.4%)
High risk	5 (23.8%)
Unknown	1 (4.8%)
Prior autologous transplant (%)
Yes	1 (4.8%)
No	20 (95.2%)
Donor type (%)
Related donor	5 (23.8%)
Unrelated donor	16 (76.2%)
Sex mismatch^† (%)
M → M	10 (47.6%)
M → F	3 (14.3%)
F → M	4 (19.0%)
F → F	4 (19.0%)
Degree of HLA match (%)
10/10	20 (95.2%)
9/10	1 (4.8%)
Median KPS (range)	80 (70–100)
Median HCT-CI (range)	1 (0–5)
Cytomegalovirus status (%)
Patient or donor +	11 (52.4%)
Both patient and donor +	5 (23.8%)
Both patient and donor negative	4 (19.0%)
Unknown	1 (4.8%)
ABO mismatched	8
Median CD34 cell dose infused (10^6 cells/kg recipient) (range)	6.0 (1.5–11.3)

†Donor → Patient.
Abbreviations: HCT-CI: hematopoietic cell transplantation comorbidity index; KPS: Karnofsky performance score; NHL: non-Hodgkin lymphoma.
*Disease relapse-risk classification based on standard ASBMT criteria (available at http://www.asbmt.org/displaycommon.cfm?an=1&subarticlenbr=35/ (Last accessed February 1, 2013)).